IndustryCompany release

Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal

Gedeon Richter · Mon 16 Nov 2026

Hungarian drugmaker signs a scheme implementation deed to buy ASX-listed Mayne Pharma at AUD 6.40 a share, gaining a US women's health and dermatology portfolio.

Gedeon Richter has signed a Scheme Implementation Deed to acquire all of Mayne Pharma (ASX:MYX), the companies said on 16 November 2026. The price is AUD 6.40 per share in cash, valuing the target at about AUD 604 million and representing a premium of roughly 99% to Mayne's previous closing price.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release: Gedeon Richter ↗

Article written by VigiEye from the official source (Gedeon Richter). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →